Congress Presentations
Stay informed about the latest scientific and medical research from Axsome.
American College of Neuropsychopharmacology (ACNP) Annual Meeting
Tampa, FL | December 03 - 06, 2023
AXS-05 | Major Depressive Disorder
ACNP Poster: Impact of AXS-05 (dextromethorphan-bupropion) on Depressive Symptoms, Anxiety, and Quality of Life in Patients with One Prior Treatment Failure: Results from the EVOLVE Long-Term, Open-Label Study
AXS-05 | Major Depressive Disorder
ACNP Poster: Evaluation of AXS-05 (dextromethorphan-bupropion) in Major Depressive Disorder Using the Interest-Activity Domain
AXS-05 | Major Depressive Disorder
Dr. Roger McIntyre, MD, FRCPC describes the “Evaluation of AXS-05 (dextromethorphan-bupropion) in Major Depressive Disorder Using the Interest-Activity Domain” ACNP 2023 poster
AXS-05 | Major Depressive Disorder
Online Figure for the “Evaluation of AXS-05 (dextromethorphan-bupropion) in Major Depressive Disorder Using the Interest-Activity Domain” ACNP 2023 poster
AXS-05 | Major Depressive Disorder
Dr. Rakesh Jain, MD describes the "Assessment of Withdrawal Symptoms After Discontinuation of AXS-05 (Dextromethorphan-Bupropion) Treatment: Results From the GEMINI Trial" ACNP 2023 Poster
AXS-05 | Major Depressive Disorder
ACNP Poster: Assessment of Withdrawal Symptoms After Discontinuation of AXS-05 (Dextromethorphan-Bupropion) Treatment: Results From the GEMINI Trial
AXS-05 | Major Depressive Disorder
Dr. Greg Mattingly, MD describes the “Impact of AXS-05 (dextromethorphan-bupropion) on Depressive Symptoms, Anxiety, and Quality of Life in Patients with One Prior Treatment Failure: Results from the EVOLVE Long-Term, Open-Label Study” ACNP 2023 Poster
